New Vaccine-Drug combo takes on Hard-to-Treat myeloma

NCT ID NCT06799026

Recruiting now Disease control Sponsor: David Avigan Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests whether combining a personalized cancer vaccine (made from a patient's own tumor and immune cells) with the drug elranatamab is safe and feasible for people with multiple myeloma that has returned or stopped responding to prior treatments. Up to 25 participants will receive the vaccine along with elranatamab and a growth factor. The main goals are to see if the vaccine can be made successfully and to monitor for serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dendritic cell/myeloma fusion vaccine plus elranatamab
What this could lead to: If successful, this combination could offer a new treatment option for patients with multiple myeloma that has stopped responding to standard therapies.
What could go wrong: This is a very early phase 1 trial with only 25 participants, so the main goals are safety and feasibility. It is too soon to know if the combination will be effective, and there are risks of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA REFRACTORY MULTIPLE MYELOMA RELAPSE MULTIPLE MYELOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.